State Marijuana Legalization Aids Research Very Little

Recent federal announcements serve as reminders that in the US policy continues to outpace science when it comes to cannabis.

Written byAshley Yeager
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

ABOVE: © ISTOCK.COM, CASARSAGURU

It took psychiatrist Staci Gruber four years to wrangle approval to run a clinical trial testing whether a liquid cannabinol product administered orally can ease symptoms of anxiety. She had to get the okay from the US Food and Drug Administration, the Drug Enforcement Administration, and the National Institute on Drug Abuse.

Cannabis research, she tells The Scientist, is “not for the faint of heart.”

Eleven states and Washington, DC, have legalized recreational and medical marijuana use, with Illinois being the latest to join in January 2020, and 19 have legalized medical marijuana. It is a popular drug—a survey of nearly 170,000 adults published today (September 20) in JAMA reports that around 8 percent of respondents use marijuana, and nearly 4 percent do so daily. Yet despite its ubiquity in American society, researchers say their hands remain tied by a decades-old federal law classifying cannabis and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Ashley started at The Scientist in 2018. Before joining the staff, she worked as a freelance editor and writer, a writer at the Simons Foundation, and a web producer at Science News, among other positions. She holds a bachelor’s degree in journalism from the University of Tennessee, Knoxville, and a master’s degree in science writing from MIT. Ashley edits the Scientist to Watch and Profile sections of the magazine and writes news, features, and other stories for both online and print.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies